JEMPERLI is an immunotherapy that may help you fight certain types of advanced or returned endometrial cancer.

Learn how JEMPERLI may work for previously-treated advanced or returned dMMR endometrial cancer after chemo containing platinum.

Discover how JEMPERLI treats dMMR endometrial cancer that has returned or spread (advanced) after chemotherapy containing platinum and cannot be treated by surgery or radiation.

JEMPERLI + carboplatin and paclitaxel (CP): The FIRST AND ONLY FDA-approved immunotherapy combination proven to help patients with newly-diagnosed advanced or …

Learn about the risks and side effects associated with JEMPERLI in combination with carboplatin and paclitaxel. See full Safety & Prescribing Information.

Find information on what you may expect when taking JEMPERLI for previously-treated dMMR advanced or returned endometrial cancer after chemo containing platinum.

Discover more information about Together with GSK Oncology, a support program that may be able to help you and your doctor with access issues related to JEMPERLI.

JEMPERLI is a medicine that may treat certain cancers by working with your immune system. JEMPERLI can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work.

The most common side effects of JEMPERLI when given alone include tiredness and weakness; low red blood cell count (anemia); diarrhea; nausea; constipation; vomiting.

JEMPERLI + carboplatin and paclitaxel (CP): The FIRST AND ONLY FDA-approved immunotherapy combination proven to help patients with newly-diagnosed advanced or returned endometrial cancer LIVE LONGER*